Klarsen specializes in data marketing for customer winning and engagement. Thanks to its qualified data and proprietary technologies, it allows its customers to increase their marketing performance and net sales. Klarsen disposes of proprietary assets and qualified and reactive databases, in its network of partners and on its own.

Employees

Sector

IT Services & Consulting

More about the company

Quotes

Date	Price	Change	Volume
26-09-04	€0.8520	-4.27%	12,995
26-09-03	€0.8900	-2.41%	20,832
26-09-02	€0.9120	-6.94%	32,951
26-09-01	€0.9800	-1.01%	58,185
26-08-31	€0.9900	-8.76%	32,009

Real-time Euronext Paris

More quotes

Market Closed - Euronext Paris 11:55:00 2026-09-04 EDT			5-day change	1st Jan Change
0.8520 ^EUR	-4.27%		-35.45%	-1.84%

11-03	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-04-29	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Market Cap	2.88M 3.34M 2.71M 2.47M 4.62M 316M 4.64M 31.98M 12.41M 162M 12.55M 12.28M 522M	P/E 2023	3.28x	P/E 2024	-86x
Enterprise Value	3.96M 4.6M 3.72M 3.4M 6.36M 434M 6.38M 43.99M 17.07M 223M 17.27M 16.89M 718M	EV / Sales 2023	1.67x	EV / Sales 2024	0.82x
Free-Float	99.21%	Yield 2023 *	-	Yield 2024	-

Markets		Quality
Euronext Paris	ALKLA	Real-time
Deutsche Boerse AG	4YA	Delayed
Börse Stuttgart	4YA	Delayed
Boerse Muenchen	4YA	Real-time

11-03	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-04-29	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-10-15	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-04-29	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-03-15	Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development	MT
23-11-07	Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results	MT
23-10-27	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2023	CI
23-04-27	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-03-09	Acticor Biotech Secures Funding Until November After EUR12 Million Equity Raise; Stock Sinks 17%	MT
22-12-23	Acticor Biotech Seeks To Meet With US FDA Over Phase 2/3 Study Of Stroke Drug	MT
22-12-14	Twitter to shut down newsletter product Revue next year	RE
22-12-05	Acticor Biotech Wins EU Health Agency Nod For Phase 2/3 Stroke Study Design	MT
22-10-05	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2022	CI

Klarsen Stock

Stocks

ALKLA

FR0011038348

IT Services & Consulting

Valuation : Klarsen

Chart: Klarsen

Latest news : Klarsen

Press Releases : Klarsen

News in other languages : Klarsen

Quotes and Performance

Price Extremes

Managers and Directors : Klarsen

Latest insider transactions

Other IT Services & Consulting

Financials

Company Profile

Quotes

03-03	Klarsen : ALKLA information relative au nombre total de droits de vote et d'actions composant le capital	PU
02-25	Klarsen : ALKLA-Information relative au nombre de droits de vote et actions composant le capital	PU
12-10	Klarsen : ALKLA-Attribution gratuite de BSA	PU
12-09	Klarsen : ALKLA-ACTIVITE 3T2025	PU
11-27	Klarsen : ALKLA-Résultat augmentation de capital	PU

08-27	Klarsen : ALKLA – Présentation webinaire du 27/08/2026 – Support
08-27	Klarsen : Assemblée générale – 29 Septembre 2026
08-19	Bourse : série de résultats en Europe, flambée d'Unitree et puces Nvidia en Chine
08-18	Klarsen nomme un nouveau DG pour sa filiale ITL Datamarketing
08-18	Klarsen : ALKLA – Olivier Cornelis nommé Directeur Général d’ITL – 18 Août 2026

1 day	-4.27%
1 week	-35.45%
Current month	-13.94%
1 month	+42.00%
3 months	+63.85%
6 months	-20.74%
Current year	-1.84%

1 week	0.85	1.1
1 month	0.56	1.68
Current year	0.22	1.68
1 year	0.22	1.68
3 years	0.22	3.75
5 years	0.22	4.03
10 years	0.11	5.4

Manager	Title	Age	Since
Brice Gazeau CEO	Chief Executive Officer	-	-
Patrice Coffe DFI	Director of Finance/CFO	57	2008-06-30
Jean-Pierre Domingo CTO	Chief Tech/Sci/R&D Officer	-	2012-12-31

Director	Title	Age	Since
Patrice Coffe BRD	Director/Board Member	57	2010-06-13
Gérard Parrou BRD	Director/Board Member	74	2014-06-26
Frédéric Bartoli BRD	Director/Board Member	-	2011-03-22

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/15/22	Parrou Julien	Buy		2,617	0.0790%
2/28/22	Julien Parrou-Duboscq	Buy	Chief Executive Officer	3,011	0.0909%
2/28/22	Julien Parrou-Duboscq	Buy	Chief Executive Officer	3,000	0.0905%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KLARSEN	-4.27%	-35.45%	-2.74%	-77.46%	3.43M
IBM	-0.07%	-0.27%	-4.95%	+58.61%	221B
ACCENTURE PLC	-3.32%	-1.59%	-26.23%	-42.79%	118B
SNOWFLAKE INC.	-3.64%	+2.82%	+51.99%	+111.60%	124B
TATA CONSULTANCY SERVICES LTD.	-0.69%	+2.47%	-25.62%	-31.82%	88.8B
RELX PLC	-2.06%	-1.95%	-25.04%	+1.39%	63.25B
INFOSYS LIMITED	-0.03%	+1.73%	-23.60%	-21.74%	48.42B
FUJITSU LIMITED	+2.77%	+3.92%	+12.23%	+112.36%	42.31B
NEC CORPORATION	+2.09%	+1.96%	+11.37%	+210.64%	40.31B
HCL TECHNOLOGIES LIMITED	-1.94%	+0.89%	-11.78%	+9.07%	37.76B
Average	-1.13%	-1.38%	-4.44%	+32.99%	78.37B
Weighted average by Cap.	-1.21%	+1.97%	-2.86%	+40.18%

	2023	2024
Net sales	5.03M 5.84M 4.73M 4.32M 8.08M 551M 8.1M 55.88M 21.68M 283M 21.93M 21.45M 911M	6.31M 7.33M 5.94M 5.42M 10.15M 692M 10.17M 70.16M 27.23M 355M 27.54M 26.94M 1.14B
Net income	2.75M 3.2M 2.59M 2.36M 4.42M 302M 4.43M 30.58M 11.87M 155M 12M 11.74M 499M	-47.76K -55.51K -44.94K -41.05K -76.8K -5.24M -77.01K -531K -206K -2.69M -208K -204K -8.66M
Net Debt	-634K -737K -597K -545K -1.02M -69.61M -1.02M -7.05M -2.74M -35.72M -2.77M -2.71M -115M	1.08M 1.26M 1.02M 929K 1.74M 119M 1.74M 12.02M 4.66M 60.84M 4.72M 4.61M 196M